“If you haven't used HYDROS before, or if you're concerned about doing bigger glands or tackling more difficult cases, I think we've shown in our first 35-40,000 cases that Aquablation, the therapy, is a valid therapy,” says Lewis S. Kriteman, MD, FACS.
"The idea is to keep improving these devices," says Ana Lidia Flores-Mireles, PhD.
"One of the things I think that's really interesting is we're seeing the development of a lot of AI predictive models of who might progress to urosepsis and who might be at higher risk for progression of their infection to have greater health consequences," says A. Lenore Ackerman, MD, PhD.
"Of those that met the primary end point, they remained free of progression at a median of 31 months and counting," says Nicholas G. Nickols, MD, PhD.
"The evolution is continuing, now with a decade of human use of Aquablation, we can now take this to a same-day procedure––discharge the same calendar day," says Kevin C. Zorn, MD, FRCSC, FACS.
"[One] of the things that makes the technology really interesting, in my mind, for CVAC, is that it's not just a suction device," says Thomas Chi, MD, MBA.
“What probably should be happening is that we should be reserving these antibiotics only for those situations in which someone has a multi-drug-resistant infection for which there are options that are not available otherwise,” says A. Lenore Ackerman, MD, PhD.
"[Although] we were very excited about the finding in this study showing that Unfold AI could be superior to MRI in detecting extracapsular disease, our next step is to validate this in a multi-institutional, prospective manner," says Shyam Natarjan, PhD.
"My specific career path is really not at all like my mentors, and I think that's fine, actually. It's great, because I'm doing what I want to do and not feeling constrained to go down any particular pathway," says Stacy Loeb, MD, MSc, PhD (Hon).
Panelists discuss how the treatment landscape for metastatic castration-resistant prostate cancer (mCRPC) is rapidly evolving through advancements in precision medicine and novel therapies, while emphasizing the importance of ongoing education for community oncologists to stay updated on these changes.
The panel explores promising biomarker research that has the potential to significantly impact patient care in prostate cancer.
Prostate cancer specialists share their insights on anticipated future advancements that could significantly influence prostate cancer management strategies.
Michael Gorin, MD discusses the impact of next-day imaging and the potential imaging improvements as physicians await the results of the CLARIFY trial.
Michael Gorin, MD provides the background and results of two key imaging trials that reviewed the efficacy of this new copper-based agent.
"From a revenue, profit and loss perspective, actually, in many instances, they anticipate that physicians may actually make more money using the second-generation CVAC device compared to traditional ureteroscopy, depending on your payer mix and your practice," says Thomas Chi, MD, MBA.
The TiNivo-2 trial demonstrated that rechallenging ICI therapy does not improve outcomes in patients with renal cell carcinoma.
“We already have very effective ARPIs available around the world, and this will add to those therapeutic options to try to tailor patients based on their needs [and] their particular profiles,” says Fred Saad, MD, FRCS.
“I think that these data in this approximately 700 patient trial consolidates and makes a strong case for the role of pembrolizumab in the adjuvant setting,” says Guru P. Sonpavde, MD.
“Today, we're presenting the results of this analysis, and we show that patients who have a high Decipher score derive significant benefit from docetaxel,” says Gerhardt Attard, MD, PhD, FRCP.
"It clearly shows that blocking HIF-2α is a meaningful way of interacting with disease biology in clear cell renal cell carcinoma," says Eric Jonasch, MD.
“[We’re] trying to anticipate with a smartwatch some of the catastrophic blood pressure changes and things that happen in these patients,” says Matthew J. Mellon, MD, FACS.
Thomas Chi, MD, MBA, discusses advantages to the CVAC System.
Panelists discuss how to address the challenges in providing optimal care for mCRPC patients and how barriers may vary between different healthcare settings, such as rural vs. urban and private vs. public.
Panelists discuss how the dosing and administration of different abiraterone formulations vary, how food-related effects impact treatment efficacy, and strategies to manage these effects for optimal patient outcomes.
The key opinion leaders explore strategies for integrating newly available diagnostic tests into the existing treatment paradigm and patient journey.
The panel examines the significance of biomarkers in assessing therapy outcomes for prostate cancer patients, while also exploring the concept of absolute benefit in metastasis risk when adding androgen deprivation therapy (ADT) to radiation therapy for newly diagnosed cases.
"I think it's going to help younger or less experienced urologists get more proficient at this procedure faster. That's where the AI is going to come into play," says Lewis S. Kriteman, MD, FACS.
A medical expert discusses how emerging copper-based developments in PSMA imaging, particularly the 64Cu-SAR-bisPSMA agent, offer advancements in tumor detection and imaging logistics compared to traditional agents.
A medical expert discusses how advancements in PSMA PET imaging, including the development of agents like 64Cu-SAR-bisPSMA, address current challenges in sensitivity and logistical issues, potentially enhancing tumor detection and patient outcomes.
“In the period where a patient receives a diagnosis of favorable intermediate-risk cancer or higher and doesn't know what to do, there is a big unmet need/gap that we aim to serve with Unfold AI,” says Shyam Natarajan, PhD.
